Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Could This Be a “Suckers” Rally?

Everyone I know who is not involved in the stock market or has little knowledge about it is calling me and asking what stocks, indexes, and commodities to buy because everything is so cheap and dividends are juicy again. Just look at the market sentiment chart, and price c...
Chris Vermeulen | April 15, 2020 |

Cracking the Code to Society’s Most Feared Disease

Even more so than cancer, it’s the one disease that we all fear the most. The thought of falling prey to Alzheimer’s disease and to the inevitable desecration of our mind is something that makes even the bravest among us shudder. ...
Marc Davis | February 7, 2020 |

NervGen: Are amazing human trial results leaking out?

“We are very excited! We are very, very excited!” So says Dr. Monica Perez, who is running the first human trial for a potential new wonder drug being developed by a tiny but well-financed life sciences start-up, NervGen Pharma Corp. ...
Knox Henderson | July 2, 2024 |

NervGen Pharma: A “Blockbuster Drug” in the Making?

It has the potential to be one of the most disruptive pharmaceutical drug therapies of the modern era, especially for treating Alzheimer’s disease. And that gives it considerable “blockbuster drug” potential – a tantalising opportunity tha...
Marc Davis | June 25, 2021 |

Is this stunning 'evidence' that NervGen has the goods?

This could be the signal that tiny NervGen Pharma Corp. (TSX-V:NGEN; OTCQX:NGENF) is destined to be one of the top performing biotech startup stocks this year. It came in a seemingly innocuous podcast interview about the company’s ongoing Phase 1b/2...
Knox Henderson | February 1, 2024 |

Can NervGen keep a lid on explosive news?

Speculation of early “evidence” of successful proof-of-concept human trials sparks stock rallies Trial volunteers taking a placebo are offered the real deal in a follow-up trial as a “reward” The company&Clo...
Knox Henderson | March 20, 2024 |

InMed Shares Trade Up 25% After Becoming First to Advance Cannabinol into Clinical Trials

InMed Pharmaceuticals shares traded 25% higher after reporting that it is the first to advance cannabinol into therapeutic clinical trials. Vancouver-based clinical stage biopharmaceutical company InMed Pharmaceuticals Inc. (IN:TSX; IMLFF:OTCQX) , which is engaged in...
Streetwise Reports | January 21, 2020 |

Revolutionary biopharma company makes waves across the globe

The following is a transcription of the above video, and The Market Online has edited it for clarity . The Market Online recently caught up with NurExone Biologic Inc (TSXV:NRX) , a revolutionary biopharmaceutical company developing regenerative medicine therapies,...
Lyndsay Malchuk | July 10, 2024 |

Could There Finally Be an Effective Treatment for Alzheimer's Disease?

ProMIS' preclinical treatment could possibly outshine Biogen's candidate. Finding an effective treatment for Alzheimer's disease has been elusive as many seemingly promising avenues of research did not prove out in clinical trials. Biogen Inc. (BIIB:NASDAQ) appeared...
Streetwise Reports | November 7, 2019 |

Technical Analyst: Gold at Resistance Level

Technical analyst Clive Maund discusses the effects of geopolitics on the price of gold. In this update I am not going to repeat the points made in the last fairly comprehensive update , instead we are going to focus on the importance of the resistance level just ab...
Streetwise Reports | January 7, 2020 |
1 2 3 4 5 6 7 8 9 10 ...